News

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...
By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...
A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...
More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...
What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and ...
Polymorphs, or different crystalline forms of the same drug, can be selected for distinct properties and patented. A recent court ruling, however, adds new complexity, write experts at Finnegan.
Driving growth in a family-owned pharma company requires a balance of progress and preservation, writes Merz Therapeutics CEO Stefan König.
Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesnt have to be that way, writes Anastasia Christianson, Ph.D.
Cuts to federal research funding at universities and research organizations are pushing academic scientists into life sciences entrepreneurship. Experts at Sidley offer tips for the transition.
Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets to form a U.S.-based Newco, explain experts at Orrick.
Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate risk, and comply with emerging AI regulations.